Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies. Brepocitinib also achieved statistically significant and clinically meaningful benefit on all key secondary endpoints, including measurements of sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning. These results were achieved despite a substantially more aggressive steroid taper than precedent NIU trials.
Oct 21 · 11:00·GlobeNewswire
Finance · Healthcare
TORONTO, Oct. 21, 2026 -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in November.
Oct 21 · 11:00·GlobeNewswire
Finance · Biotech & pharma
First and only PD-1 inhibitor plus antibody-drug conjugate regimen approved in the European Union (EU) for patients with MIBC regardless of cisplatin eligibility RAHWAY, N.J., October 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commiss
Oct 21 · 10:45·Business Wire
AI · SaaS
Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that five studies involving its AI-powered pathology platform, Lunit SCOPE, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. -- Five studies to be presented, with key research examining AI-based biomarker assessment and tumor micr
Oct 21 · 10:34·MarketersMEDIA
SaaS · Healthcare
Burjeel Cancer Institute in Abu Dhabi has opened the world’s first clinical site for BioSapien’s MediChip, a biodegradable implant delivering chemotherapy directly to tumors. Its Phase I trial will evaluate safety in localized rectal cancer, exploring potential reductions in systemic exposure and treatment-related complications. -- Announced at Abu Dhabi Health Summit Burjeel Cancer Institute at Burjeel Medical City
Oct 21 · 10:31·MarketersMEDIA
Healthcare · Industrial
News Summary: NVIDIA and the UW Medicine Institute for Protein Design debut RFD4-Proteina, a new open model that combines programmable protein design with search capabilities, unlocking new frontiers in biology. Siemens Healthineers is advancing the next generation of adaptive radiotherapy, using NVIDIA intelligence to increase access to life-saving cancer care with agentic co-planning, patient-specific simulation … Continue reading "Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care"
Oct 21 · 10:15·PressReach
Biotech & pharma
According to the latest market analysis published by The Insight Partners, the Non-Invasive Drug Delivery Market is registering a CAGR of 9.4% from 2026 to 2034. The Non-Invasive Drug Delivery Market Research study enhances the decision-making capabilities and helps to ...
Read more
Oct 21 · 10:14·PR News Releaser
Finance · Healthcare
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 MIAMI, October 21, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-clas
Oct 21 · 10:05·Business Wire
Healthcare · Biotech & pharma
Munich, Düsseldorf, Germany, Oct. 21, 2026 -- Munich, Düsseldorf, October 21, 2026 — MC Services AG, a leading international corporate communications and investor relations firm for life sciences and healthcare, will support BIO-Europe® 2026 as media partner. Taking place in Cologne, Germany, November 9-11, 2026, MC Services invites international, national and regional media, coordinates interview opportunities with attending biotech and pharma executives and experts, and facilitates background conversations that give journalists direct access to the companies, perspectives and developments shaping the biopharma sector.
Oct 21 · 10:00·GlobeNewswire
Finance · Biotech & pharma
Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer FREMONT, Calif., October 21, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision on
Oct 21 · 10:00·Business Wire